{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:23:46Z","timestamp":1780496626493,"version":"3.54.1"},"reference-count":20,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T00:00:00Z","timestamp":1583193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Facial Plastic Surgery &amp; Aesthetic Medicine"],"published-print":{"date-parts":[[2020,4,1]]},"abstract":"<jats:sec>\n                    <jats:title>Importance:<\/jats:title>\n                    <jats:p>Exploring potential methods of controlling postoperative rhinoplasty pain with non-narcotic medications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To examine the effects of celecoxib in reducing pain and possible opioid consumption after rhinoplasty surgery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Setting, and Participants:<\/jats:title>\n                    <jats:p>This is a prospective cohort study of 51 consecutive patients who had undergone rhinoplasty surgery between July 2018 and May 2019 by a single facial plastic surgeon. A questionnaire regarding pain medication usage and complications was given to each patient at his or her initial 1-week postoperative visit. Patients were separated into groups based on whether celecoxib had been used perioperatively or not.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes and Measures:<\/jats:title>\n                    <jats:p>In addition to demographic information, the following outcome measures were recorded for each group: type(s) of pain medications used, total opioid consumption, refills required, surgical complications, and related analgesic adverse effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Of the 51 patients included, 17 patients were provided celcoxib. Mean oxycodone\u2013acetaminophen tablets taken in the celecoxib cohort was 4.2 (CI\u2009=\u20092.4\u20136.1), whereas mean tablets taken among controls was 14.8 (CI\u2009=\u200911.1\u201318.4) (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.0006). Mean oxycodone\u2013acetaminophen dose taken in the celecoxib cohort was 17.6\u2009mg (CI\u2009=\u20099.0\u201326.3), whereas the mean among controls was 73.8\u2009mg (CI\u2009=\u200955.5\u201392.0) (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.0001). Mean total oral morphine equivalents (OMEs) were also reduced with an average of 26.5 OME (CI\u2009=\u200913.5\u201339.4) in the celecoxib cohort and 110.7 OMEs (CI\u2009=\u200983.3\u2013138.0) in the control group (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.001). Postoperative nausea and vomiting were significantly reduced in the celecoxib cohort versus the control group (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.02). Overall, with the addition of celecoxib, there was a 76.2% decrease in milligrams of opioid use and an 83.4% decrease in incidence of nausea\/vomiting.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance:<\/jats:title>\n                    <jats:p>Oral celecoxib appears to be effective in decreasing opioid consumption and nausea\/vomiting rates after rhinoplasty without increasing surgical complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Level of Evidence:<\/jats:title>\n                    <jats:p>2<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/fpsam.2019.29014.new","type":"journal-article","created":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T17:08:15Z","timestamp":1582045695000},"page":"100-104","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["The Efficacy of Oral Celecoxib Following Surgical Rhinoplasty"],"prefix":"10.1177","volume":"22","author":[{"given":"Christopher Ian","family":"Newberry","sequence":"first","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, University of Utah School of Medicine, Salt Lake City, Utah."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary C.","family":"McCrary","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, University of Utah School of Medicine, Salt Lake City, Utah."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric W.","family":"Cerrati","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, University of Utah School of Medicine, Salt Lake City, Utah."},{"name":"Division of Facial Plastic and Reconstructive Surgery, Department of Otolaryngology\u2013Head and Neck Surgery, University of Utah School of Medicine Salt Lake City, Utah."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,3,3]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamafacial.2018.0999"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(03)00152-8"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2012.9596"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamafacial.2014.351"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12630-014-0275-x"},{"issue":"11","key":"e_1_3_4_7_2","first-page":"988","article-title":"Association of celecoxib use with decreased opioid requirements after head and neck cancer surgery with free tissue reconstruction","volume":"144","author":"Carpenter PS","year":"2018","unstructured":"Carpenter PS, , Shepherd HM, , McCrary H, et al. Association of celecoxib use with decreased opioid requirements after head and neck cancer surgery with free tissue reconstruction. JAMA Otolaryngol Head Neck Surg. 2018; 144(11):988\u2013994.","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1213\/ane.0b013e3181618831"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02782.x"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2011.01196.x"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-9-77"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00266-008-9230-y"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjy050"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.4037\/ccn2015440"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/939431"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/2325967119838873"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1186\/s41038-018-0128-x"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jccw.2014.03.001"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.04.058"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.13.jrv60011"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamafacial.2017.1034"}],"container-title":["Facial Plastic Surgery &amp; Aesthetic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/fpsam.2019.29014.new","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/fpsam.2019.29014.new","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/fpsam.2019.29014.new","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T06:23:20Z","timestamp":1777443800000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/fpsam.2019.29014.new"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,3]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4,1]]}},"alternative-id":["10.1089\/fpsam.2019.29014.new"],"URL":"https:\/\/doi.org\/10.1089\/fpsam.2019.29014.new","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.737431435.793573032","asserted-by":"object"}]},"ISSN":["2689-3614","2689-3622"],"issn-type":[{"value":"2689-3614","type":"print"},{"value":"2689-3622","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,3]]}}}